TP04HN106

· Talengen Institute of Life Sciences

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TP04HN106, covering 2024-12-20 to 2024-12-20. Get the full timeline:

Most recent: Clinical Trial Update: TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis [Phase 1, Phase 2]